Open AccessUse of autologous peripheral blood mononuclear cells in a case of diabetic foot
Author(s) -
Giacoma Di Vieste
Publication year - 2019
Publication title -
j. amd
Language(s) - English
Resource type - Journals
ISSN - 2532-4799
DOI - 10.36171/jamd19.22.4.07
Subject(s) - medicine , peripheral blood mononuclear cell , amputation , critical limb ischemia , gangrene , diabetic foot , surgery , ischemia , diabetes mellitus , peripheral , vascular disease , arterial disease , endocrinology , biochemistry , in vitro , chemistry
The implantation of peripheral blood mononuclear cells (PBMNC), an autologous concentrate with high angiogenic and regenerative capability is an innovative therapeutic approach in the treatment of peripheral arteriopathies of patients with critical limb ischemia. We describe the case of a 59-year-old patient with type 2 diabetes mellitus who had a gangrene of the right toe. The critical limb ischemia required an angioplasty that was ineffective due to the widespread, obstructive, intractable and calcific disease of the distal tibial vessels and of the foot vessels. Because of the therapeutic failure, being the patient otherwise candidated for major amputation, it was decided to use a PBMNC therapy. This approach consists in the inoculation in the perilesional area and along the vascular axes of the affected lower limb of a concentrate of mononuclear cells taken from peripheral blood by using a selective filtration separation system. The patient underwent to amputation of the first necrotic toe and three PBMNC treatment sessions with complete surgical wound haeling and limb rescue. KEYWORDS diabetes mellitus; critical limb ischemia; mononuclear cells therapy.